Psoriatic Arthritis: Symptoms, Diagnosis, Treatment Options, and Living Well

Psoriatic arthritis (PsA) is a chronic inflammatory spondyloarthropathy affecting ~30% of psoriasis patients. It involves peripheral joints, axial skeleton, entheses, skin, nails, and eyes. Early diagnosis and treat-to-target strategy prevent irreversible joint damage.

Clinical Domains (CASPAR Criteria)

  • Peripheral arthritis: Asymmetric oligoarthritis, dactylitis (sausage digits), symmetric polyarthritis (RA-like).
  • Axial disease: Inflammatory back pain (nocturnal, improves with activity), sacroiliitis.
  • Enthesitis: Achilles, plantar fascia, costochondral, pelvic.
  • Dactylitis: Diffuse digit swelling (flexor tenosynovitis + synovitis).
  • Skin/nail psoriasis: Plaques, pitting, onycholysis, oil spots.
  • Extra-articular: Uveitis, IBD, cardiovascular/metabolic comorbidity.

Diagnosis

  • CASPAR criteria: Inflammatory articular disease + ≥3 points (current psoriasis=2, personal/family history=1, nail dystrophy=1, dactylitis=1, RF negative=1, juxta-articular bone formation=1).
  • Imaging: X-ray (pencil-in-cup, osteolysis, periostitis), US/MRI (synovitis, enthesitis, bone edema – earlier detection).
  • Labs: CRP/ESR (elevated 40–50%), RF/anti-CCP negative (usually), HLA-B27 (axial subset).

Treatment: Treat-to-Target (T2T) – Minimal Disease Activity (MDA) or Remission

1. NSAIDs

First-line for mild peripheral symptoms; no disease modification. GI/CV/renal monitoring.

2. Conventional Synthetic DMARDs (csDMARDs)

  • Methotrexate (MTX): Anchor drug; 15–25 mg/week + folic acid. Modest skin/joint benefit; limited axial/entheseal efficacy.
  • Sulfasalazine, Leflunomide: Alternatives.

3. Biologic DMARDs (bDMARDs) – High Efficacy, Rapid Onset

ClassAgentsKey Notes
TNF inhibitorsAdalimumab, Etanercept, Infliximab, Certolizumab, GolimumabBroad domain coverage; first-line biologic; TB screening mandatory
IL-17 inhibitorsSecukinumab, Ixekizumab, BrodalumabSuperior skin (PASI 100); caution in IBD
IL-23 inhibitorsGuselkumab, Risankizumab, TildrakizumabExcellent skin, joint; less IBD risk; quarterly dosing
IL-12/23 inhibitorUstekinumabEstablished; q12 wk dosing
CTLA4-IgAbataceptT-cell co-stimulation blockade; IV/SC

4. Targeted Synthetic DMARDs (tsDMARDs)

  • Apremilast (PDE4 inhibitor): Oral; modest efficacy; GI side effects; no lab monitoring.
  • JAK inhibitors (Tofacitinib, Upadacitinib): Oral; broad efficacy; boxed warnings (infection, VTE, malignancy, CV events); reserve after bDMARD failure.

5. Local Therapy

  • Intra-articular glucocorticoids (flare bridge).
  • Enthesis injection (US-guided).

6. Non-Pharmacologic

  • Physical/occupational therapy (joint protection, splinting, exercise).
  • Weight loss (BMI >25 worsens response).
  • Smoking cessation (reduces efficacy, ↑ CVD).
  • Cardiometabolic risk management.

Monitoring & Comorbidities

  • q3–6 mo: DAPSA/MDA, labs (CBC, LFT, renal), TB screen (annual if biologic).
  • Screen: CVD, diabetes, NAFLD, depression, IBD, uveitis (annual ophthalmology).
  • Vaccinations: Update pre-biologic; avoid live vaccines.

Pregnancy & PsA

Certolizumab (no placental transfer) preferred. MTX, leflunomide, JAKi contraindicated. Plan with rheumatologist/OB pre-conception.

PsA is manageable. Early rheumatology referral, shared decision-making, and holistic care enable full, active lives.

Tumors - Related Articles